Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views
The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition.
The assessments used different frameworks
Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for Adverse Events. A moderate or severe patient-rated symptom was not automatically a clinician-rated grade three or four event.
The reported pattern depended on the measure
Patient-rated adverse events of special interest were more frequent with THC/CBD, including the moderate-to-severe category. Clinician-rated grade three or four events and serious adverse events occurred with more similar frequencies between groups. The investigators attributed no serious adverse event to THC/CBD.
Different categories do not cancel each other
The absence of an attributed serious event does not erase bothersome sedation or dizziness. Equally, a checklist symptom should not be relabeled as a serious medical event without the relevant criteria. This distinction matters for treatment claims and functional assessments: antiemetic benefit, symptom burden, medical seriousness and capacity for a safety-sensitive task require separate evidence. The trial supplies short-term observations under monitored treatment, rather than a single universal percentage for cannabis safety.
Related analysis: the trial’s main results and limitations.
